Navigation Links
Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
Date:7/29/2008

y and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable la
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. ThreeWire Expands Presence in the Pharmaceutical Arena
3. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
4. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
8. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
10. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...0 Novavax, Inc. (Nasdaq:...ed today that the company will be presenting at th...ber 2, 2009 at 12:30 pm local time at The New York...ew of the company,s business strategy, research an... link to the live audio only presentation can be a...
(Date:11/30/2009)...wire/ -- Dr. Jessica Torrente, Assistant Professor...cal Center in Washington, D.C., demonstrated the i...g (BSGI) in clinical practice as an adjunct imagin...y at the annual meeting of the Radiological Societ...he exhibit was to demonstrate how BSGI is used in ...
(Date:11/30/2009)... BioMarin Pharmaceutical ...d and Drug Administration (FDA) has granted orphan...), amifampridine phosphate, for the rare autoimmun.... 3,4-DAP has previously received orphan drug des...ommittee for Medicinal Products for Human Use of t...
(Date:11/30/2009)..., Nov. 30 Exiqon A/S (NASDAQ OMX C... Medical School ICCB-Longwood Screening Facility (...g Center of Excellence. ICCB-L supports investiga...pitals and institutions, for high-throughput scree...icroRNAs are a novel class of small, non-coding RN...
Breaking Biology Technology:NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3
...7 The market for congestive heart,failure (CHF) d...7, and is,expected to reach $30 billion by 2017, a...Congestive Heart Failure: Major World Markets, Vol...driven by three factors: an,increased incidence of...n,search of targeted therapies which is creating o...
...ril 17 Spherix Incorporated,(Nasdaq: SPEX ) anno...perations. Mr. Brown will be monitoring and overse...rial regarding the use of Naturlose(R) as a,treatm...as allowed Spherix,to terminate its agreement with...r full control of the clinical trial and its pivot...
...7 SPO Medical Inc. (OTC:,SPOM), a leading develop...r,use in portable monitoring devices, today announ...Capital Ventures (ACV), a leading provider of,comp... cap community, as an,investor relations consultan...ve Officer of SPO Medical,commented, "As we contin...
Other Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Spherix Hires Key Employees 2SPO Medical Retains American Capital Ventures for Investor Relations Services 2SPO Medical Retains American Capital Ventures for Investor Relations Services 3
(Date:11/26/2009)...ies has shown that closing schools in the event of...ficant role in reducing illness transmission. Rese...fectious Diseases compared opportunities for infe...g that they were reduced when schools are shut. ,...Belgium, led a team of European researchers in usi...
(Date:11/25/2009)...ay be used to boost resistance to, or slow, the de...edicine researchers report in a study published in..., Parkinson,s disease is caused by a degeneratio...nown as the substantia nigra, which is responsible...opamine in late-stage Parkinson,s causes symptoms ...
(Date:11/25/2009)...s some 250 million liters of blood through the bod...he heart have to be extremely durable. The researc...ir of the Department of Medicine III at Heidelberg...tus), has discovered a protein that is responsible...the sarcomere. In cooperation with other researche...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 1Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4984 9GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 1GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 2GENova appoints Dr Philip Gould to Scientific Advisory Board 56991 3Opto electronic nose sniffs out toxic gases 9902 1Opto electronic nose sniffs out toxic gases 9902 2Opto electronic nose sniffs out toxic gases 9902 3
...ghting like a girl or fighting like a boy is hardw...in the Nov. 19 Nature Neuroscience advance online ...l School and the Institute of Molecular Pathology ...s "fruitless" is a key factor underlying sexual di...ne in an unlikely new animal model for understandi...
...e Shoklo Malaria Research Unit (SMRU), Thailand, w...28 December entitled "Twenty Years of Malaria Rese...nationally-renowned experts and featuring talks an...a, from epidemiology to therapeutics and from immu...Research Unit (SMRU) in Mae Sot, Thailand, which b...
...searchers at the Albert Einstein College of Medici...n grant from the National Cancer Institute to stud...t with surrounding tissues, cells and chemicals in... invade other areas of the body in the process kno...ohn Condeelis, co-chair of anatomy and structural ...
Other Biology News:Fighting like a girl or boy determined by gene in fruit flies 2Fighting like a girl or boy determined by gene in fruit flies 3Twenty Years of Malaria Research: Outcomes and Perspectives 2World's smallest cancer detection device 2
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Dulbecco's Modified Eagle's Medium - high glucose (DME) from Sigma-Aldrich
...r routine procedures. Hollandes contains formaldeh...l decalcify small bone specimens. Tissue that is f...ith most stains, and the cupric acetate in the sol...nophil and endocrine cell granules so that less ly...
...tograph/Mass Spectrometer, utilizing many of the h...igh throughput and excellent productivity, providi...io. Like the GCMS-QP2010 Plus, the GCMS-QP2010s fe...um separation, 20 temperature ramps, and both scan...
Biology Products: